

# MINI MED SCHOOL: VACCINES

---

PEYTON THOMPSON, MD, MSCR  
PEDIATRIC INFECTIOUS DISEASES  
UNC HOSPITAL  
FEBRUARY 24<sup>TH</sup>, 2020




# OUTLINE

---


- **History of Vaccines**
- Basic Principles of Vaccines
- Cases
- Common Concerns about Vaccines

# BRIEF HISTORY OF VACCINES



# BRIEF HISTORY OF VACCINES

---




# OUTLINE

---


- History of Vaccines
- **Basic Principles of Vaccines**
- Cases
- Common Concerns about Vaccines

# BASIC PRINCIPLES OF VACCINATION

**D** Mortality due to vaccine-preventable diseases



# Trends in invasive pneumococcal disease among children aged <5 years old, 1998–2015



\*PCV13 serotype: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

# WE HAVE **MANY** EFFECTIVE VACCINES

---

## Routine Childhood Vaccines

- Diphtheria, Tetanus, acellular Pertussis (DTaP/Tdap)
- *Haemophilus influenzae* type b (Hib)
- Hepatitis A
- Hepatitis B
- Human Papilloma virus (HPV)
- Influenza
- Measles, Mumps and Rubella (MMR)
- Meningococcal
- Pneumococcal
- Polio
- Rotavirus
- Varicella

## Other Vaccines

- Adenovirus
- Anthrax
- Tuberculosis (BCG)
- Cholera
- Japanese Encephalitis (JEE)
- Meningitis B (MenB)
- Rabies
- Shingles
- Typhoid
- Vaccinia (Smallpox)
- Yellow Fever



# CDC VACCINE SCHEDULE, AGES 0-18 YEARS

## Birth to 15 Months

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos
<a href="#">Hepatitis B</a> ⓘ (HepB)	1 <sup>st</sup> dose	2 <sup>nd</sup> dose			←3 <sup>rd</sup> dose→			
<a href="#">Rotavirus</a> ⓘ (RV) RV1 (2-dose series); RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See <a href="#">notes</a>			
<a href="#">Diphtheria, tetanus, &amp; acellular pertussis</a> ⓘ (DTaP: <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose			←4 <sup>th</sup> dose→
<a href="#">Haemophilus influenzae type b</a> ⓘ (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See <a href="#">notes</a>		←3 <sup>rd</sup> or 4 <sup>th</sup> dose, See <a href="#">notes</a> →	
<a href="#">Pneumococcal conjugate</a> ⓘ (PCV13)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		←4 <sup>th</sup> dose→	
<a href="#">Inactivated poliovirus</a> ⓘ (IPV: <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	←3 <sup>rd</sup> dose→			
<a href="#">Influenza (IIV)</a> ⓘ or <a href="#">Influenza (LAIV)</a> ⓘ					Annual vaccination 1 or 2 doses			
<a href="#">Measles, mumps, rubella</a> ⓘ (MMR)					See <a href="#">notes</a>		←1 <sup>st</sup> dose→	
<a href="#">Varicella</a> ⓘ (VAR)							←1 <sup>st</sup> dose→	
<a href="#">Hepatitis A</a> ⓘ (HepA)					See <a href="#">notes</a>		←2-dose series, See <a href="#">notes</a> →	
<a href="#">Meningococcal</a> ⓘ (MenACWY-D: ≥9 mos; MenACWY-CRM: ≥2 mos)			See <a href="#">notes</a>					
<a href="#">Tetanus, diphtheria, &amp; acellular pertussis</a> ⓘ (Tdap: ≥7 yrs)								
<a href="#">Human papillomavirus</a> ⓘ (HPV)								
<a href="#">Meningococcal B</a> ⓘ (MenB)								
<a href="#">Pneumococcal polysaccharide</a> ⓘ (PPSV23)								

## 18 Months to 18 Years

Vaccines	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 yrs
<a href="#">Hepatitis B</a> ⓘ (HepB)	←3 <sup>rd</sup> dose→								
<a href="#">Rotavirus</a> ⓘ (RV) RV1 (2-dose series); RV5 (3-dose series)									
<a href="#">Diphtheria, tetanus, &amp; acellular pertussis</a> ⓘ (DTaP: <7 yrs)	←4 <sup>th</sup> dose→			5 <sup>th</sup> dose					
<a href="#">Haemophilus influenzae type b</a> ⓘ (Hib)									
<a href="#">Pneumococcal conjugate</a> ⓘ (PCV13)									
<a href="#">Inactivated poliovirus</a> ⓘ (IPV: <18 yrs)	←3 <sup>rd</sup> dose→			4 <sup>th</sup> dose					
<a href="#">Influenza (IIV)</a> ⓘ or <a href="#">Influenza (LAIV)</a> ⓘ	Annual vaccination 1 or 2 doses				Annual vaccination 1 dose only				
<a href="#">Measles, mumps, rubella</a> ⓘ (MMR)				2 <sup>nd</sup> dose					
<a href="#">Varicella</a> ⓘ (VAR)				2 <sup>nd</sup> dose					
<a href="#">Hepatitis A</a> ⓘ (HepA)	← 2-dose series, See <a href="#">notes</a> →								
<a href="#">Meningococcal</a> ⓘ (MenACWY-D: ≥9 mos; MenACWY-CRM: ≥2 mos)	See <a href="#">notes</a>					1 <sup>st</sup> dose		2 <sup>nd</sup> dose	
<a href="#">Tetanus, diphtheria, &amp; acellular pertussis</a> ⓘ (Tdap: ≥7 yrs)						Tdap			
<a href="#">Human papillomavirus</a> ⓘ (HPV)						See <a href="#">notes</a>			
<a href="#">Meningococcal B</a> ⓘ (MenB)	See <a href="#">notes</a>								
<a href="#">Pneumococcal polysaccharide</a> ⓘ (PPSV23)	See <a href="#">notes</a>								

# OUTLINE

---

- History of Vaccines
- Basic Principles of Vaccines
- **Cases**
- Common Concerns about Vaccines

# CASE #1

---

- A 23 year-old Burmese male develops liver dysfunction and goes on to develop liver cancer. He is on the liver transplant list but has not yet received his transplant.
- Further testing reveals that he is hepatitis B positive.
- What are the typical manifestations of hepatitis B?
- What could have prevented this disease course?



# HEPATITIS B: ACQUISITION

---


- Viral infection (hepadnavirus)
- Blood-borne pathogen
- Acquired by 2 major routes of transmission:
  - Vertical (mother-to-child)
  - Horizontal (person-to-person)



# HEPATITIS B: CLINICAL

---

- Acute infection:
  - Ranges from no symptoms to acute hepatitis
  - May develop jaundice (yellowing of the skin), scleral icterus (yellowing of the whites of the eyes), joint pain, skin rashes etc.
  - Infection can clear or remain in the body (chronic)




© Fitzgerald Health Education Associates, Inc.

# HEPATITIS B: CHRONIC INFECTION

---




**9 of 10** infants infected in the first year of life develop chronic infection



**1 of 4** chronically infected infants die in adulthood from cirrhosis or hepatocellular carcinoma

# VIRAL HEPATITIS B IN THE WORLD


257m  
GLOBAL



# HEPATITIS B: PREVENTION

---

- Hepatitis B vaccine
  - **First vaccine to prevent cancer!!**





# CASE #2

---

- Parents of a 7 year-old unvaccinated female bring her to see you for a rash. The family returned from a trip to Paris 5 days ago. The child developed “cold-like” symptoms on the flight home, and then broke out in this pictured full-body rash last night.
- What is this illness?
- What could have been done to prevent it?



# MEASLES: ACQUISITION

---

- Viral infection (paramyxovirus)
- One of the most contagious infectious diseases!
- Most contagious 4 days prior to rash appearance through 4 days after onset
- Airborne spread (similar to tuberculosis)




# MEASLES: CLINICAL

---

Phase 1



Phase 2




Phase 3

Healing

## Complications

- Ear infections
- Pneumonia
- Encephalitis (1:1,000)
- Death (1-3:1,000)


Figure 1.2 Clinical features of primary measles infection – time course from onset of illness



Contagious period

# Number of Measles Cases Reported by Year

2010-2019\*\* (as of December 31, 2019)





NC DEPARTMENT OF  
**HEALTH AND  
HUMAN SERVICES**

**ROY COOPER** • Governor

**MANDY COHEN, MD, MPH** • Secretary

**MARK T. BENTON** • Assistant Secretary for Public Health

Division of Public Health

To: North Carolina Clinicians  
From: Erica Wilson, MD, MPH, Medical Epidemiologist  
Subject: Measles in Traveler in Guilford County (2 pages)  
Date: October 11, 2019

**Summary:**

A case of measles has been diagnosed in an individual who traveled through Guilford County while contagious on October 2<sup>nd</sup> and 3<sup>rd</sup>.

Individuals could have been exposed at the Piedmont Triad International Airport and at the Greensboro Wyndham Garden Hotel on those dates. Every effort is being made to contact persons with known exposure; however, it is possible that other unrecognized contacts may have been exposed at these locations.

# MEASLES: VACCINATION

---

- Combined with mumps and rubella (MMR)



12-15  
months



4-6  
years

# CASE #3

---

- A 15 year-old male comes to the emergency room with 1 day of fever, chills, and flu-like symptoms. He tests negative for influenza. He is discharged home with instructions to drink plenty of fluids and take Tylenol & Advil as needed for fever.
- The next day, his parents find him in his room unresponsive and he has a purple-colored rash on his arms and legs.
- What is the cause of his illness?
- What could have been done to prevent it?





# MENINGOCOCCEMIA: ACQUISITION

---

- Bacterial infection (*Neisseria meningitidis*)
- Spread by respiratory droplets
  - Contagious up to 24 hours after starting effective antibiotics
- Most cases are sporadic
- Outbreaks may occur in child care settings, colleges, military recruit camps

# MENINGOCOCCEMIA: CLINICAL

---

- Abrupt onset
- Fever, chills, body aches
- Meningitis in 50%
- Bloodstream infection in 35-40%
- Characteristic rash
- Complications: loss of limbs, hearing loss, shock, death



# MENINGOCOCCEMIA: VACCINATION

---

- Routine vaccine:



- MenB vaccine:
  - Approved for use in children  $>10$  years; recommended between ages 16-23

# CASE #4

---

The parents of a 17-year-old college student in your practice call to ask your advice. The student awoke this morning to find a bat flying around his dormitory room. He and his roommate opened the window and the bat flew out. He feels well and on self-examination noticed no skin lesions or bite marks. His immunizations are up to date, including receipt of diphtheria-tetanus-pertussis vaccine at 11 years of age.

Of the following, the BEST course of action is:

- A. Begin a 5-day course of amoxicillin-clavulanic acid (antibiotic)
- B. Begin a rabies vaccine series
- C. Give a tetanus vaccine booster
- D. Monitor his skin for signs of new skin lesions over the next 2 weeks
- E. Provide reassurance

# CASE #4

---

The parents of a 17-year-old college student in your practice call to ask your advice. The student awoke this morning to find a bat flying around his dormitory room. He and his roommate opened the window and the bat flew out. He feels well and on self-examination noticed no skin lesions or bite marks. His immunizations are up to date, including receipt of diphtheria-tetanus-pertussis vaccine at 11 years of age.

Of the following, the BEST course of action is:

- A. Begin a 5-day course of amoxicillin-clavulanic acid (antibiotic)
- B. Begin a rabies vaccine series**
- C. Give a tetanus vaccine booster
- D. Monitor his skin for signs of new skin lesions over the next 2 weeks
- E. Provide reassurance

# RABIES: ACQUISITION

---

- Viral infection (rhabdoviridae)
- Most U.S. cases transmitted by bats
  - May not have bite marks
  - If a bat is found in a child's room, he or she should be considered exposed and should get a vaccine series
- Other animals: dogs and cats (more rare with routine rabies vaccination), raccoons, skunks, foxes, coyotes, bobcats
  - Unlikely in rodents and rabbits



# RABIES: CLINICAL

---

- Rapidly progressive neurological impairment
  - Characterized by hydrophobia (fear of water)
- Universally fatal if not vaccinated promptly



# RABIES: VACCINATION

---

- Prevention is key, as we do not have effective treatment!!



- High-risk individuals (such as veterinarians) should receive rabies vaccination as prophylaxis



# OUTLINE

---

- History of Vaccines
- Basic Principles of Vaccines
- Cases
- **Common Concerns about Vaccines**

# 5 COMMON CONCERNS ABOUT VACCINATIONS

Questions that parents bring to their provider regarding vaccines

<http://whyimmunizekids.org/role-playing-video-clips/>

Full Video: Addressing Vaccine-Hesitant Parents



# I. ARE VACCINES SAFE?

- Safety monitoring:
  - National Immunization Hotline 1-800-CDC-INFO
  - VAERS (Vaccine Adverse Event Reporting System)
  - VSD (Vaccine Safety Datalink)
  
- Absolutely NO link to autism
  - 2014 Meta-Analysis

**THE LANCET**

The Lancet, [Volume 351, Issue 9103](#), Pages 637 - 641, 28 February 1998  
doi:10.1016/S0140-6736(97)11096-0

**This article was retracted**

**RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children**

Dr [AJ Wakefield](#) FRCS [a](#), [SH Murch](#) MB [b](#), [A Anthony](#) MB [a](#), [J Linnell](#) PhD [a](#), [DM Casson](#) MRCP [b](#), [M Malik](#) MRCP [b](#), [M Berelowitz](#) FRCPsych [c](#), [AP Dhillon](#) MRCPath [a](#), [MA Thomson](#) FRCP [b](#), [P Harvey](#) FRCP [d](#), [A Valentine](#) FRCP [e](#), [SE Davies](#) MRCPath [a](#), [JA Walker-Smith](#) FRCP [a](#)

**Summary**

**Background**  
We investigated a consecutive series of children with chronic enterocolitis and regressive developmental disorder.

**Methods**  
12 children (mean age 6 years [range 3–10], 11 boys) were referred to a paediatric gastroenterology unit with a history of normal development followed by loss of acquired skills, including language, together with diarrhoea and abdominal pain. Children underwent gastroenterological, neurological, and developmental assessment and review of developmental records. Ileocolonoscopy and biopsy sampling, magnetic-resonance imaging (MRI), electroencephalography (EEG), and lumbar puncture were done under sedation. Barium follow-through radiography was done where possible. Biochemical, haematological, and immunological profiles were examined.

## 2. AREN'T THE INGREDIENTS IN VACCINES DANGEROUS?

- Thimerosal:
  - No link to autism
  - No longer an ingredient in most vaccines
- Aluminum:
  - Necessary to induce an immune response
  - Total amount of aluminum in 1st 6 months:
    - Vaccines: 4-6mg
    - Breastmilk: ~10mg in breastmilk
    - Formula: ~40mg (~120mg in soy based formula)



# THIMEROSAL (CONT.)

DTaP-HepB-IPV	Pediarix (GlaxoSmithKline Biologicals)	Free	Never contained more than a Trace of Thimerosal, approval date for thimerosal-free formulation 1/29/2007
DTaP-IPV/Hib	Pentacel (sanofi pasteur Ltd.)	Free	Approved June 20, 2008, never contained thimerosal
DTaP-IPV	KINRIX (Glaxo SmithKline Biologicals)	Free	Approved October 8, 2009, never contained thimerosal
Pneumococcal conjugate	Prennar (Wyeth Pharmaceuticals Inc.)	Free	Never contained Thimerosal
	Prennar 13 (Wyeth Pharmaceuticals Inc.)	Free	Approved February 24, 2010, never contained thimerosal
Inactivated Poliovirus	IPOL (Sanofi Pasteur, SA)	Free	Never contained Thimerosal
Varicella (chicken pox)	Varivax (Merck & Co, Inc.)	Free	Never contained Thimerosal
Mumps, measles, and rubella	M-M-R-II (Merck & Co, Inc.)	Free	Never contained Thimerosal
Mumps, measles, rubella and varicella	ProQuad (Merck & Co., Inc.)	Free	Approved September 6, 2005, never contained thimerosal.
Hepatitis A	Havrix (GlaxoSmithKline Biologicals)	Free	Never contained thimerosal
	Vaqta (Merck & Co., Inc.)	Free	Never contained thimerosal
Hepatitis B	Recombivax HB (Merck & Co, Inc.)	Free	08/27/99
	Engerix B (GlaxoSmithKline Biologicals)	Free	03/28/00, approval date for thimerosal-free formulation 1/30/2007

# 3. WON'T MULTIPLE VACCINES AT ONCE "OVERWHELM" MY CHILD'S IMMUNE SYSTEM?

- Multiple vaccines work WITH the immune system to BOOST it, not to overload it
- Normal newborn is exposed to 100,000 antigens a day (versus 150 antigens total in childhood vaccine series)
- Fewer antigens in vaccines now than in past, despite larger total number of vaccines

***I grow stronger with use.***

*The immune system is like muscle  
and vaccines are like exercise.*

*Vaccines prepare my immune  
system so it is fit and ready  
to fight off disease – just  
like exercise makes my  
muscles fit, strong, and  
ready to work.*



TABLE 2.


Number of Immunogenic Proteins and Polysaccharides Contained in Vaccines Over the Past 100 Years

1900		1960		1980		2000	
Vaccine	Proteins	Vaccine	Proteins	Vaccine	Proteins	Vaccine	Proteins/Polysaccharides
Smallpox*	~200	Smallpox	~200	Diphtheria	1	Diphtheria	1
<b>Total</b>	<b>~200</b>	Diphtheria†	1	Tetanus	1	Tetanus	1
		Tetanus‡	1	WC-Pertussis	~3000	AC-Pertussis¶¶	2-5
		WC-Pertussis§	~3000	Polio	15	Polio	15
		Polioll	15	Measles¶¶	10	Measles	10
		<b>Total</b>	<b>~3217</b>	Mumps#	9	Mumps	9
				Rubella**	5	Rubella	5
				<b>Total</b>	<b>~3041</b>	Hib††	2
						Varicella‡‡	69
						Pneumococcus§ §	8
						Hepatitis B  Verbar;	1
						<b>Total</b>	<b>123-126</b>

Taken taken from: Offit P, et al. Addressing parents' concerns: Do multiple vaccines overwhelm or weaken the infant's immune system? *Pediatrics*. 2002;109:124-129.

## 4. ISN'T NATURAL IMMUNITY BETTER?

- For some infections, natural immunity is better because it lasts longer  
BUT...
- It comes at a price (deafness, brain damage, pneumonia, paralysis, death)
  - Risk of encephalitis from measles is 1 in 1,000...versus 1 in 1,000,000 from the MMR vaccine





# 5. IT'S MY RIGHT TO DECIDE WHAT'S BEST FOR MY CHILD.


- Yes it definitely is, AND you need to be aware of the risks of not vaccinating your child
  - Lethality of these diseases
- What about homeschooling?
  - Laws differ by state
  - “It’s a small world...”



# HOW HERD IMMUNITY WORKS...

**FIGURE 3**

Reported measles cases by municipality, 1 May–28 August 2013 (panel A, n=1,226) and vaccination coverage of first MMR vaccine dose by municipality<sup>a</sup> for birth cohort 2010 at the age of two years (panel B, n=184,230), the Netherlands



MMR: measles-mumps-rubella.

<sup>a</sup> There are 30 municipalities with MMR-1 vaccination coverage below 90%, of which 29 are within the 'Bible belt'. The other municipality is Vaals, in the far south-east of the Netherlands. A considerable number of the infants living in Vaals receive their vaccinations in Germany and are therefore not registered in the Dutch vaccination registration, which explains the low vaccination coverage (84.3%).

# QUESTIONS?

---



[Jenner and the Milkmaid - Steve Meshnick](#)